Document Detail


Multimarker Risk Assessment Including Osteoprotegerin and CXCL16 in Acute Coronary Syndromes.
MedLine Citation:
PMID:  23023373     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: CXCL16 and osteoprotegerin (OPG) both predict mortality in acute coronary syndromes. We hypothesized that a combination of CXCL16 and OPG concentrations would add prognostic information to the Global Registry of Acute Coronary Events (GRACE) score in patients hospitalized for acute coronary syndromes. METHODS AND RESULTS: We assessed the associations between circulating OPG and soluble CXCL16 levels, obtained within 24 hours of admission (day 1) and after 3 months, and mortality, heart failure and reinfarction in 1322 patients admitted with acute coronary syndromes. After adjustment for the GRACE score, medication, diabetes mellitus and sex, the combination of high values (fourth quartile) for OPG and CXCL16 at baseline was associated with increased short-term (3 months) cardiovascular mortality (hazard ratio, 3.28; 95% CI, 1.84-5.82; P<0.0001. The combined high values were also significantly associated with the long-term (median 91 months) prognosis after adjustment, with hazard ratios 2.18 for cardiovascular mortality (95% CI, 1.62-2.92; P<0.0001), and 2.22 for heart failure (95% CI, 1.67-2.96; P<0.0001). These long-term associations remained significant after further adjustment for left ventricular ejection fraction, C-reactive protein, and pro B-type natriuretic peptide (pro brain natriuretic peptide). For 635 patients with blood samples within 24 hours and at 3 months, the combination of high CXCL16 and OPG values (fourth quartile) in the early or stable phase was of a similar order associated with mortality and morbidity beyond 3 months. CONCLUSIONS: Circulating CXCL16 and OPG are independent predictors of long-term mortality and heart failure development in acute coronary syndromes patients, even after extensive adjustments. Their combination gives more information than either marker alone.
Authors:
Anna M Jansson; Marianne Hartford; Torbjørn Omland; Thomas Karlsson; Per Lindmarker; Johan Herlitz; Thor Ueland; Pål Aukrust; Kenneth Caidahl
Related Documents :
6367683 - Status of exercise stress testing after myocardial infarction.
23914033 - Acute eosinophilic myocarditis with dramatic response to steroid therapy: the central r...
19106083 - Genetic determinants of response to clopidogrel and cardiovascular events.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-27
Journal Detail:
Title:  Arteriosclerosis, thrombosis, and vascular biology     Volume:  -     ISSN:  1524-4636     ISO Abbreviation:  Arterioscler. Thromb. Vasc. Biol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-10-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9505803     Medline TA:  Arterioscler Thromb Vasc Biol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Molecular Medicine and Surgery, Karolinska Institutet and Departments of Clinical Physiology and Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden; Departments of Clinical Physiology and Cardiology, Sahlgrenska Academy and University Hospital, Göteborg, Sweden; Division of Medicine, Akershus University Hospital, Lørenskog, Norway; Research Institute of Internal Medicine, Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway; and Faculty of Medicine, University of Oslo, Oslo, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Alanine-glyoxylate aminotransferase-2 metabolizes endogenous methylarginines, regulates NO, and cont...
Next Document:  Myeloid Deletion of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Increases Atherosclerosis and...